Ariel Global Fund on Pharmaron Beijing Co., Ltd.
Thesis
Ariel expects Pharmaron to benefit from a broadening recovery in pharmaceutical outsourcing. Results exceeded expectations and management raised its full-year revenue outlook following stronger orders in laboratories, clinical services and CDMO operations. The momentum in contract development and manufacturing helps establish a more durable growth path. AI-enabled drug discovery adds upside to an already integrated service platform spanning drug research and development.
“growing exposure to AI-enabled drug discovery presents an attractive incremental opportunity.”
Key risks
- Biopharmaceutical clients could slow outsourcing orders
- Execution of sustained CDMO growth across businesses
- AI-enabled drug discovery monetization may develop more slowly